News Outlets Discuss Experimental COVID-19 Treatments From Regeneron, Eli Lilly, Trump’s Experience, Efforts To Provide Drugs To Low-Income Nations

New York Times: Trump’s Testimonial Is a Double-Edged Sword for Regeneron (Thomas et al., 10/9).

POLITICO: Regeneron CEO: Trump ‘is a case of one’ and ‘weakest evidence’ for Covid-19 treatment (O’Brien, 10/11).

Reuters: Eli Lilly in deal to supply COVID-19 drugs to low-income countries (Mishra, 10/8).

STAT: Listen: ‘They gave me Regeneron’: How Trump’s case of Covid-19 affects biotech, medicine, and the FDA (Garde et al., 10/8).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270 | Email Alerts: | |

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.